Mayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe

MT Newswires Live

May 14, 2025

Mayne Pharma Group (ASX:MYX) said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.

It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.

It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.

Its shares fell 13% on market close on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535992096"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535992096\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535992096?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 14:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535992096","market":"sg","top_or_hot":-1,"title":"Mayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe","media":"MT Newswires Live","content":"<html><body><p> Mayne Pharma Group (ASX:MYX) said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.</p><p>It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.</p><p>It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.</p><p>Its shares fell 13% on market close on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-14 14:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mayne Pharma Group (ASX:MYX) said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.</p><p>It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.</p><p>It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.</p><p>Its shares fell 13% on market close on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2535992096","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535992096","pubTimestamp":1747204293,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mayne Pharma Group  said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.Its shares fell 13% on market close on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","MYX.AU":"MAYNE PHARMA GROUP LTD","BK7096":"制药"},"translate_title":"梅恩制药集团将在规定时间内回复美国FDA信函","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYX.AU":0.9},"content_text":"Mayne Pharma Group (ASX:MYX) said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.Its shares fell 13% on market close on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}